Eupraxia reaches 120-patient enrollment target in Phase 2b trial of EP-104GI for eosinophilic esophagitis
EPRX•Eupraxia Pharmaceuticals reached its 120-patient enrollment target for the Phase 2b RESOLVE trial of EP-104GI on October 12, 2026. Interim results covering symptoms, tissue findings and safety are expected in December 2026.
1. Trial enrollment complete
Eupraxia Pharmaceuticals reached its 120-patient enrollment target for the Phase 2b RESOLVE trial of EP-104GI for eosinophilic esophagitis on October 12, 2026. The company expects interim results covering symptoms, tissue findings and safety in December 2026.
2. Safety observations
Safety observations to date indicate EP-104GI has been generally well tolerated, with no treatment-related serious adverse events across both trial phases. Periodic data reviews indicate no increase in enrollment is needed to meet the study’s statistical objectives.
